
Fifteen patients with advanced zzso were treated with escalating doses of zzso beta zzso 17 zzso zzso zzso ranging from zzso to 500 X zzso zzso were administered according to a dosage escalation scheme by zzso push twice weekly zzso 1 week after an initial zzso for a planned minimum of 5 weeks, to be continued as a function of zzso zzso effects were broad in scope but generally low in zzso They included fever, zzso zzso zzso zzso zzso and mild zzso of serum zzso and zzso In one patient, transient zzso with zzso zzso zzso and fever increased somewhat with increasing zzso zzso of up to 500 X zzso zzso were tolerated without severe zzso A maximum tolerated dose was not zzso zzso zzso followed a zzso zzso curve, with a distribution phase zzso of 9 minutes and an elimination phase zzso of 103 zzso zzso zzso by the zzso technique were present in seven of 15 zzso zzso of zzso did not correlate with toxicity or zzso zzso zzso levels were increased 2 and 24 hours after the initial dose, with a trend toward higher increments with higher zzso zzso zzso responses were seen in two patients with zzso 

